Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications

por Sznol, Mario, Rizvi, Naiyer
Publicado 2023

Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant

por Cecchini, Michael, Sznol, Mario, Seropian, Stuart
Publicado 2015

Melanoma: A model for testing new agents in combination therapies

por Ascierto, Paolo A, Streicher, Howard Z, Sznol, Mario
Publicado 2010

Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy

por Flies, Dallas B., Sandler, Britt J., Sznol, Mario, Chen, Lieping
Publicado 2011

Phase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers

por Kunos, Charles A., Chu, Edward, Makower, Della, Kaubisch, Andreas, Sznol, Mario, Ivy, Susan Percy
Publicado 2017

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy

por Hughes, Jing, Vudattu, Nalini, Sznol, Mario, Gettinger, Scott, Kluger, Harriet, Lupsa, Beatrice, Herold, Kevan C.
Publicado 2015

Combination immunotherapy: Where do we go from here?

por Overacre, Abigail E., Kurtulus, Sema, Sznol, Mario, Pardoll, Drew M., Anderson, Ana, Vignali, Dario A. A.
Publicado 2015

Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives—a meeting report

por Pinto, Catarina, Bergmann, Michael, Briukhovetska, Daria, Nuessler, Volkmar, Sznol, Mario, von Bergwelt-Baildon, Michael, Kobold, Sebastian
Publicado 2020

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

por Dhodapkar, Kavita, Verma, Rakesh, Sznol, Mario, Boddupalli, Chandra Sekhar, Gettinger, Scott, Kluger, Harriet, Dhodapkar, Madhav, Das, Rituparna
Publicado 2014

Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis

por Dhodapkar, Kavita, Bar, Noffar, Boddupalli, Chandra Sekhar, Kadaveru, Krishna, Mai, Zifeng, Deng, Yanhong, Sznol, Mario, Dhodapkar, Madhav
Publicado 2015

A novel anti-melanoma SRC-family kinase inhibitor

por Halaban, Ruth, Bacchiocchi, Antonella, Straub, Robert, Cao, Jian, Sznol, Mario, Narayan, Deepak, Allam, Ahmed, Krauthammer, Michael, Mansour, Tarek S.
Publicado 2019

Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerab...

por Belzer, Annika, Pach, Jolanta, Mortlock, Ryland D., Clune, James, Olino, Kelly, Sznol, Mario, Bhatia, Aarti, Burtness, Barbara, Christensen, Sean, Leventhal, Jonathan S.
Publicado 2023

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

por Rubinstein, Jill C, Sznol, Mario, Pavlick, Anna C, Ariyan, Stephan, Cheng, Elaine, Bacchiocchi, Antonella, Kluger, Harriet M, Narayan, Deepak, Halaban, Ruth
Publicado 2010

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization

por Kluger, Harriet M, McCarthy, Mary M, Alvero, Ayesha B, Sznol, Mario, Ariyan, Stephan, Camp, Robert L, Rimm, David L, Mor, Gil
Publicado 2007

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells

por Halaban, Ruth, Zhang, Wengeng, Bacchiocchi, Antonella, Cheng, Elaine, Parisi, Fabio, Ariyan, Stephan, Krauthammer, Michael, McCusker, James P, Kluger, Yuval, Sznol, Mario
Publicado 2010

A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer

por Lazova, Rossitza, LaBerge, Greggory S., Duvall, Eric, Spoelstra, Nicole, Klump, Vincent, Sznol, Mario, Cooper, Dennis, Spritz, Richard A., Chang, Joseph T., Pawelek, John M.
Publicado 2013

Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma

por Klemen, Nicholas D., Wang, Melinda, Rubinstein, Jill C., Olino, Kelly, Clune, James, Ariyan, Stephan, Cha, Charles, Weiss, Sarah A., Kluger, Harriet M., Sznol, Mario
Publicado 2020

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC

por Ross-Macdonald, Petra, Walsh, Alice M, Chasalow, Scott D, Ammar, Ron, Papillon-Cavanagh, Simon, Szabo, Peter M, Choueiri, Toni K, Sznol, Mario, Wind-Rotolo, Megan
Publicado 2021

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

por Smithy, James W., Moore, Lauren M., Pelekanou, Vasiliki, Rehman, Jamaal, Gaule, Patricia, Wong, Pok Fai, Neumeister, Veronique M., Sznol, Mario, Kluger, Harriet M., Rimm, David L.
Publicado 2017

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

por Blank, Christian U., Wong, Deborah J., Ho, Thai H., Bauer, Todd M., Lee, Carrie B., Bene-Tchaleu, Fabiola, Zhu, Jing, Zhang, Xiaosong, Cha, Edward, Sznol, Mario
Publicado 2021